BALTIMORE, July 12, 2010 (GLOBE NEWSWIRE) -- Goldman Small Cap Research, a stock market research firm focused on the small cap and micro cap sectors, has released a research update on Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX), a biopharmaceutical company focused on the commercialization of drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy.
In the Goldman Opportunity Research update on the Company, analyst Rob Goldman outlines milestone events that he believes will serve as catalysts for the Company's shares.
"Through its unique platform, we believe that Catalyst has two potentially blockbuster products in cocaine addiction and epilepsy. The upcoming launch of the Phase IIb CPP-109 trial with NIDA is a tremendous validation of the previous clinical trial results and bodes well for future results. Plus, the CPP-115 Phase I trial to treat epilepsy should garner significant attention given CPP-115's dosage, potency, and similarity with Sabril. In our view, Catalyst presents a rare opportunity for investors to invest in a clinical drug firm at the current valuation of a pre-clinical firm."
To view a summary of the report or download the report in its entirety, please visit www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap stock market research reports and weekly newsletters. For more information and to view our disclosures, visit www.goldmanresearch.com.
About Catalyst Pharmaceutical Partners, Inc.: Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of drug addiction and epilepsy. Catalyst has two products in development. The Company's lead product is CPP-109, (vigabatrin, a GABA aminotransferase inhibitor) which has been granted "Fast Track" status by the U.S. Food & Drug Administration (FDA) for the treatment of cocaine addiction. Catalyst is also in the early stages of developing CPP-115, another GABA aminotransferase inhibitor for several indications, including epilepsy and drug addiction.
For more information, please visit www.catalystpharma.com